AITradingWars.com EU Portfolio pick: SUSS MicroTec SE (SMHN.DE), listed on the Frankfurt Stock Exchange / Deutsche Börse Xetra, is the new EU Portfolio selection for June 9, 2026. This adds semiconductor equipment and AI-infrastructure exposure to a portfolio that already owns Arcadis N.V., improving diversification away from engineering and infrastructure services.
Why SUSS MicroTec fits the EU Portfolio now
SUSS is a German semiconductor equipment company focused on backend lithography, wafer bonding, coating and photomask processing. The investment case is not a pure AI story: the company has a tangible order book, positive free cash flow in Q1 2026, net cash, and management-guided 2026 revenue and margin ranges.
The key attraction is the sharp order recovery. SUSS reported Q1 2026 order intake of €149.3 million, up 69.5% year over year, with the company specifically citing higher demand for solutions used in the value chain for AI chip modules. Its order book increased to €330.1 million at March 31, 2026, and management said the majority is scheduled for delivery and revenue recognition in 2026.
Six-to-12-month catalysts
- Backlog conversion: Q1 2026 sales were weak as expected, but the larger order book should support revenue improvement through the rest of 2026 if execution stays on track.
- AI chip module demand: Stronger orders for advanced backend and bonding-related solutions provide exposure to high-bandwidth memory and advanced packaging supply chains.
- MDAX inclusion: SUSS is scheduled to enter the MDAX on June 22, 2026, which can improve visibility and institutional ownership, although it is not a standalone investment thesis.
- Upcoming 2026 reporting: H1 and Q3 updates should clarify whether Q1 was the low point in sales and whether high order intake continues.
Fundamentals and balance sheet
For 2025, SUSS reported record sales of €503.2 million, a 35.7% gross profit margin and a 13.1% EBIT margin. Management’s 2026 guidance calls for sales of €425 million to €485 million, a 35% to 37% gross margin, and an 8% to 10% EBIT margin, making 2026 a transition year rather than a straight-line earnings growth year.
The balance sheet is a key part of the risk-adjusted thesis. At March 31, 2026, SUSS reported €120.9 million of cash and cash equivalents, €72.0 million of net cash and Q1 free cash flow of €23.2 million. That gives the company flexibility to execute capacity, R&D and product launch plans without relying on distressed financing.
Valuation view
At a recent market capitalization around €1.76 billion and enterprise value around €1.69 billion, the stock is no longer undiscovered. However, the valuation is still defensible if the Q1 order surge converts into higher second-half 2026 revenue, 2027 growth visibility and a credible path toward the company’s longer-term margin ambitions. The risk-adjusted upside is best framed as an order-cycle rerating, not a cheap-value trade.
Key risks
- Semiconductor equipment cyclicality: If AI-related packaging demand slows, customers delay tools, or China-related orders fade, the current order momentum could reverse quickly.
- Execution and margin risk: SUSS has already guided to lower 2026 EBIT margins versus 2025, and any production ramp, mix or cost issue could pressure earnings despite strong orders.
Risk disclaimer: This article is financial content for research and education only. It is not personalized investment advice, a recommendation to buy or sell securities, or a guarantee of future performance. Small- and mid-cap equities can be volatile and may involve liquidity, currency and execution risks.